Recent advances in the treatment of tuberculosis
Clinical Microbiology and Infection · 2024
DOI: 10.1016/j.cmi.2023.07.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Ilaria Motta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Médecins Sans Frontières, Manson Unit, London, United Kingdom. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Medical Research Council, NIAID, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid, and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, and SHINE) and drug-resistant TB (STREAM, NiX-TB, ZeNix, and TB-PRACTECAL). Dose optimization of rifamycins and repurposed drugs has also brought hopes of further development of safe and effective regimens. Consequently, international and WHO clinical guidelines have been updated multiple times in the last years to keep pace with these advances. OBJECTIVES: This narrative review aims to summarize the state-of-the-art on treatment of drug-susceptible and drug-resistant TB, as well as recent trial results and an overview of ongoing clinical trials. SOURCES: A non-systematic literature review was conducted in PubMed and MEDLINE, focusing on the treatment of TB. Ongoing clinical trials were listed according to the authors' knowledge and completed consulting clinicaltrials.gov and other publicly available websites (www.resisttb.org/clinical-trials-progress-report, www.newtbdrugs.org/pipeline/trials). CONTENT: This review summarizes the recent, major changes in the landscape for drug-susceptible and drug-resistant treatment, with a specific focus on their potential impact on patient outcomes and programmatic TB management. Moreover, insights in host-directed therapies, and advances in pharmacokinetics and pharmacogenomics are discussed. A thorough outline of ongoing therapeutic clinical trials is presented, highlighting different approaches and goals in current TB clinical research. IMPLICATIONS: Future research should be directed to individualize regimens and protect these recent breakthroughs by preventing and identifying the selection of drug resistance and providing widespread, affordable, patient-centred access to new treatment options for all people affected by TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Médecins Sans Frontières, Manson Unit, London, United Kingdom.
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
- Chiril Draganiuc Phthisiopneumology Institute, Chisinau, Moldova; Department of Pulmonology and Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova; Division of Clinical Infecti…
- Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape To…
- Department of Pulmonology and Allergology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of Medical Sciences, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia.
- Departments of Epidemiology, Biostatistics, Global Health and Medicine, Boston University, Boston, MA, United States.
Förderung
- Medical Research Council
- NIAID
- National Institutes of Health
- Cancer Research UK
- European Society of Clinical Microbiology and Infectious Diseases
- Wellcome Trust
Zitieren
APA
Motta, I., Boeree, M., Chesov, D., Dheda, K., Günther, G., Horsburgh, C. R., Kherabi, Y., Lange, C., Lienhardt, C., McIlleron, H. M., Paton, N. I., Stagg, H. R., Thwaites, G., Udwadia, Z., Van Crevel, R., Velásquez, G. E., Wilkinson, R. J., Guglielmetti, L., & Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (2024). Recent advances in the treatment of tuberculosis. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.07.013
Vancouver
Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR, et al. Recent advances in the treatment of tuberculosis. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2023.07.013
BibTeX
@article{Motta2024,
author = {Motta, Ilaria and Boeree, Martin and Chesov, Dumitru and Dheda, Keertan and Günther, Gunar and Horsburgh, Charles Robert and Kherabi, Yousra and Lange, Christoph and Lienhardt, Christian and McIlleron, Helen M and Paton, Nicholas I and Stagg, Helen R and Thwaites, Guy and Udwadia, Zarir and Van Crevel, Reinout and Velásquez, Gustavo E and Wilkinson, Robert J and Guglielmetti, Lorenzo and Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)},
title = {Recent advances in the treatment of tuberculosis},
journal = {Clinical Microbiology and Infection},
year = {2024},
doi = {10.1016/j.cmi.2023.07.013}
}
EUVIMED